EMA consults on revising the Guideline on Risk Assessment of Medicinal Products in Human Reproduction & Breastfeeding
By Nasir Hussain.
This draft guidance, once adopted sometime in mid-2027, will replace “Guideline on Risk Assessment of Medicinal Products on Human Reproduction and Lactation: from Data to Labelling (EMEA/CHMP/203927/2005)”.
The main aim of this revision was to reflect current standards regarding non-clinical - including the option for new approach methods (NAMs) - and clinical assessments.
Tags: Pregnancylactationbreastfeedingfertilitycontraindicationrisk minimisationnon-clinical assessmentclinical assessmentrisk assessmentSummary of Product Characteristics